FDA Accepts Supplement Application for KRYSTEXXA by Horizon Pharma
The FDA has accepted the supplemental application BLA125293 for KRYSTEXXA (pegloticase) submitted by Horizon Pharma. This application is currently under standard review priority.
Company
Pharmaceutical intelligence for Horizon Pharma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.